Browse the evidence

Physical activity attenuates the obesity-increasing genetic effects associated with the FTO locus by approximately 20-30%.

If you have a family history of obesity linked to the FTO gene, regular physical activity is not just beneficial—it is a critical counter-measure. Engaging in regular exercise can reduce the genetic impact on your BMI by 20-30%, proving that lifestyle choices actively modify genetic risk.

FTO gene variants interact with sweet beverage consumption and alcohol intake to influence obesity and blood pressure.

If you have the FTO gene variant, be particularly mindful of your intake of sweet beverages and alcohol, as these interact with your genetics to increase obesity and blood pressure risk.

Lifestyle-mediated weight loss interventions (diet and/or exercise) induce significant DNA methylation changes in blood leukocytes and adipose tissue, potentially serving as biomarkers for predicting individual response to therapy and reflecting systemic metabolic improvements.

Lifestyle changes like diet and exercise don't just change your weight; they change how your genes are expressed. This means your body's biological response to weight loss is unique and can potentially be predicted by looking at specific DNA markers before you start. Consistent lifestyle interventions can reverse obesity-associated epigenetic patterns.

Baseline DNA methylation levels can serve as prognostic biomarkers to predict which individuals will successfully lose weight in response to lifestyle interventions.

Your body's current epigenetic state might tell you how well you'll respond to a specific diet or exercise plan before you even start. This suggests a future where weight loss strategies are tailored based on your unique biological markers rather than just your current weight.

High-bar narrow stance squats increase knee extensor demand (greater knee contribution to total moment and higher vastus lateris activity) compared to low-bar wide stance squats.

If you want to prioritize your quads, use a high-bar narrow stance. If you want to prioritize your hips and glutes, switch to a low-bar wide stance. These technical changes directly shift the mechanical load to the target muscles.

GLP-1 receptor agonists reduce the risk of heart failure hospitalization, with the most significant relative risk reduction observed in patients with heart failure with preserved ejection fraction (HFpEF) who have obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese, GLP-1 medications like semaglutide or efpeglenatide may significantly reduce your risk of being hospitalized for heart failure. These drugs work by improving blood sugar, reducing weight, and lowering inflammation. While not yet a standard treatment for all heart failure, they are a promising option, especially for those with obesity.

Bile acids, particularly lithocholic acid and hyocholic acid, improve glucose tolerance by activating the GPCR GPBAR1 (TGR5) on enteroendocrine cells, leading to increased GLP-1 secretion and insulin release.

Bile acids play a crucial role in glucose regulation by activating the GPBAR1 receptor, which stimulates the release of GLP-1 and insulin. This effect is particularly pronounced after meals containing fats and cholesterol, as bile acid levels rise. Post-bariatric surgery patients often experience improved glucose tolerance due to increased circulating bile acids. Maintaining a healthy gut microbiome may also influence bile acid composition and effectiveness.

Unsaturated fatty acids, particularly omega-3 PUFAs like linoleic, oleic, and docosahexaenoic acid, stimulate insulin and glucagon secretion via activation of FFAR1 and FFAR4, improving glucose tolerance.

Incorporate unsaturated fatty acids, especially omega-3 PUFAs found in fish, nuts, and seeds, into your diet. These fatty acids activate FFAR1 and FFAR4 receptors, which can stimulate the release of insulin and glucagon, helping to regulate blood sugar levels. This is particularly beneficial for individuals with insulin resistance or type 2 diabetes.

Semaglutide improves NASH resolution in patients with stage 1-3 fibrosis but does not improve fibrosis or NASH resolution in patients with NASH-related cirrhosis.

Semaglutide can help resolve NASH in patients with early to moderate fibrosis, but it is not effective for reversing scarring in advanced cirrhosis, even if it helps with weight and metabolic markers.

Semaglutide achieves the highest response rate for NASH resolution without worsening fibrosis in clinical trials, but does not reverse fibrosis despite significant weight loss.

Semaglutide is currently the most effective drug for resolving NASH without worsening fibrosis, but it does not reverse existing fibrosis. It should be considered for patients who do not achieve goals with lifestyle changes alone, under medical supervision.

Quitting smoking after a new diagnosis of type 2 diabetes reduces the risk of cardiovascular disease and mortality, although the risk remains higher than in those who never smoked.

If you smoke, quit. Even after a diabetes diagnosis, stopping smoking lowers your risk of heart attack and death compared to continuing. While your risk might not drop to the level of someone who never smoked, it is much better than staying a smoker. Combine this with exercise for the best results.

Dietary interventions that induce weight loss decrease circulating FGF-21 levels, with the magnitude of decrease being inversely proportional to carbohydrate content (very low carbohydrate diets causing the greatest reduction).

If you are maintaining weight loss, your body's FGF-21 levels will drop, which is a good sign of improved metabolic sensitivity. Eating fewer carbohydrates (Very Low Carb) causes a larger drop in FGF-21 than Low Fat or Low Glycemic Index diets. This suggests that reducing carbs may help resolve 'FGF-21 resistance' associated with obesity, potentially improving liver health.

Decreases in FGF-21 levels during weight loss maintenance are associated with improvements in hepatic insulin sensitivity, suggesting a resolution of FGF-21 resistance.

Improving your liver's sensitivity to insulin is a key goal of weight loss. This study suggests that as your FGF-21 levels drop (which happens with weight loss, especially low-carb diets), your liver becomes more responsive to insulin. This is a positive metabolic adaptation.

Dietary intervention (weight loss maintenance) increases fasting ghrelin levels and decreases chemerin levels, independent of macronutrient composition.

After weight loss, your body naturally increases hunger signals (ghrelin) and decreases inflammation markers (chemerin). This happens regardless of whether you eat low fat, low carb, or low glycemic index foods. This is a normal physiological response to weight loss.

Tirzepatide treatment (5-15 mg once weekly) reduces albuminuria (UACR) without causing adverse changes in estimated glomerular filtration rate (eGFR) in individuals with overweight or obesity, with or without type 2 diabetes.

If you have overweight or obesity, with or without type 2 diabetes, tirzepatide (a weekly injection) has been shown to improve kidney markers (specifically reducing albuminuria) without negatively impacting kidney filtration function. This benefit was observed across different doses (5-15 mg) over 72 weeks, alongside lifestyle changes. This suggests it may be a kidney-protective option for this population, particularly those with existing elevated albuminuria.

Discontinuation of GLP-1 RA therapy is associated with significant weight regain, loss of cardiorenal protection, and an increased risk of Major Adverse Cardiovascular Events (MACE).

If you stop taking your GLP-1 medication (like Ozempic or Wegovy), you are likely to regain much of the weight you lost. More importantly, studies show that stopping these drugs increases your risk of heart attacks, strokes, and other cardiovascular events. If you are considering stopping due to side effects, talk to your doctor about adjusting the dose or switching medications rather than stopping abruptly, to protect your heart and maintain your weight loss.

Resistance exercise training in older adults preserves the capacity for myonuclear accretion (satellite cell fusion), indicating that the failure of aged muscle to hypertrophy is not caused by a lack of new nuclei or a myonuclear domain size ceiling.

If you are an older adult struggling to build muscle despite consistent resistance training, do not assume your muscle fibers have run out of capacity to grow. This research confirms that your muscles can still integrate new nuclei (via satellite cells) just as well as a younger person's. The bottleneck is likely not the structural capacity of the fiber, but rather the efficiency of protein synthesis machinery (ribosomes). Focus on high-intensity resistance training to maximize this preserved capacity.

Higher pre-diagnosis physical activity is associated with significantly lower all-cause mortality in postmenopausal women with early-stage breast cancer, but this benefit does not differ based on the number of cardiometabolic risk factors.

If you have had early-stage breast cancer, staying physically active before and after diagnosis is linked to a lower risk of dying from any cause. This benefit appears to apply whether you have metabolic risk factors (like high blood pressure or diabetes) or not. Aim for regular moderate-to-vigorous activity, such as brisk walking or recreational exercise, as measured in MET-hours per week.

Postprandial glycemic responses to identical meals are highly variable between individuals but predictable within individuals based on personal characteristics.

Recognize that your body's response to food is unique. While general guidelines exist, individual glycemic responses vary significantly. This supports the move towards personalized nutrition rather than relying on universal food labels like GI.

Combining direct patient mailings with in-clinic provider referrals significantly enhances the reach and representativeness of primary care behavioral weight loss interventions compared to passive or low-engagement strategies.

To successfully recruit patients into weight loss programs, primary care clinics should use a dual approach: send targeted mailings to eligible patients and actively encourage providers to make direct referrals during visits. This combination is more effective than either method alone, especially for reaching diverse populations. Providers should be supported with easy-to-use referral tools to minimize the time burden and ensure consistent outreach.

Resistance training improves body composition, strength, and redox balance in older hemodialysis patients, but low baseline hemoglobin (<11 g/dL) specifically impairs fat-free mass gains.

If you are on hemodialysis, resistance training is highly recommended and can improve your strength, body composition, and blood markers. However, if your hemoglobin is low (below 11 g/dL), you may not see the expected muscle growth despite training hard. In this case, treating your anemia is likely a prerequisite for maximizing muscle gains from exercise.

Tirzepatide, a GLP-1/GIP dual receptor agonist, significantly reduces HbA1c levels (up to 2.24%) and body weight (up to 11.2 kg) in patients with type 2 diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine in head-to-head trials.

Tirzepatide is a once-weekly injection for Type 2 Diabetes and obesity that significantly lowers blood sugar and promotes weight loss, often more effectively than other common medications like semaglutide or insulin. It works by mimicking hormones that regulate insulin and appetite. Common side effects like nausea are usually manageable by starting with a low dose and eating smaller, low-fat meals. Due to high costs, check for insurance coverage or assistance programs.

Individuals with unhealthy pre-pandemic lifestyle patterns (low diet quality, low physical activity) are more likely to improve their diet quality and lose weight during periods of high lifestyle disruption compared to those with healthy pre-pandemic patterns.

If you currently have unhealthy habits, a major life disruption (like a pandemic or job loss) might actually be the catalyst you need to improve your diet and lose weight, simply because you have more room to improve than someone who was already healthy. Focus on small, sustainable changes to diet quality and physical activity, as these are the key drivers of weight change during disruption.

Higher lifestyle disruption, measured by changes in diet quality, physical activity, sleep, snacking, and alcohol, is associated with greater bi-directional weight change (both loss and gain) compared to low disruption.

Major life changes tend to amplify your existing habits. If you are already active and eat well, disruption might not change much. If you are sedentary and eat poorly, disruption might lead to significant weight loss or gain. To manage weight during disruptions, focus on maintaining consistent physical activity and diet quality.